FDA approves Abilify for treating autistic irritability

11/23/2009 | Bloomberg Businessweek · RTT News

The FDA approved Abilify for treating irritability in autistic children ages 6 to 17 years. Bristol-Myers Squibb said approval was based on data from two Phase III studies that showed Abilify, when compared with a placebo, significantly improved scores on the Irritability subscale of the Aberrant Behavior Checklist.

View Full Article in:

Bloomberg Businessweek · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD